<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489969</url>
  </required_header>
  <id_info>
    <org_study_id>Neu-P11-03-PSG</org_study_id>
    <nct_id>NCT01489969</nct_id>
  </id_info>
  <brief_title>Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients</brief_title>
  <official_title>A Double-blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of Neu-P11 in Insomnia Patients Aged 18-80</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurim Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurim Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study. It is conducted using a randomized, double-blind, 3-arm placebo
      controlled, parallel group design. Eligible patients will be randomized in a 1:1:1 ratio to
      receive Neu-P11 20 mg, Neu-P11 50 mg or placebo for 4 weeks The objective of this study is to
      assess the efficacy of Neu-P11 (20 and 50mg) on sleep continuity parameters in insomnia
      patients aged 18-80 years, following the first two nights (immediate effect) and at the end
      of 4 weeks of double-blind treatment. The primary efficacy endpoint in this study is Latency
      to Persistent Sleep (LPS) measured by polysomnogram (PSG) at the first two nights of
      treatment (nights 15-16 of the study; mean of two consecutive nights recordings). The
      secondary endpoints are number of awakenings after sleep onset and the duration of wake after
      sleep onset measured by PSG at the first two nights of treatment (nights 15-16 of the study;
      mean of two consecutive nights recordings).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency to Persistent Sleep</measure>
    <time_frame>2 days</time_frame>
    <description>The primary efficacy parameter is Latency to persistent sleep (LPS) measured by the PSG at the first two nights (immediate effect) of the double blind treatment period. LPS was summarized at baseline and after two days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the two days was compared, adjusting for the baselinescore. An ANCOVA model was used. Lower score indicates reduction in latency to persistent sleep and thus considered improvement</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Awakenings (NOA)</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary efficacy parameter is number of awakenings (NOA) measured by the PSG after 28 nights of the double blind treatment period. NOA was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less awakenings and thus considered improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Wake After Sleep Onset (WASO)</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary efficacy parameter is the duration of wake after sleep onset (WASO) measured by the PSG after 28 nights of the double blind treatment period. WASO was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less waking time and thus considered improvement.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neu-P11 dose of 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neu-P11 dose of 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neu-P11</intervention_name>
    <description>1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Melatonin agonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female and aged 18-80 years (both ages included).

          2. Suffering from primary insomnia according to DSM-IV criteria (307.42 primary insomnia,
             Appendix 25.1) (based on a Sleep History Questionnaire (SHQ) that is given to the
             patient at Visit Day 0, Appendix 25.1).

          3. Reported subjective sleep latency of at least 30 minutes on at least three nights per
             week for at least one month and subjective WASO of at least 45 minutes per night on at
             least 3 nights per week for at least one month (based on the SHQ).

          4. Subjects with habitual bed time within the range of 21:00-01:00 (inclusive), as
             reported by the subject during screening on Day 0.

          5. If female of childbearing potential, using a reliable method of contraception during
             the entire study duration and for at least 3 months after study drug intake.

          6. Have not been using benzodiazepine (BZD) and non-BZD hypnotics or melatoninergic drugs
             for the past 2 weeks or more prior to Screening.

          7. Have not been using psychotropic treatments for the past 3 months or more prior to
             Screening.

          8. Are stabilized on non-psychotropic treatments for more than 3 months prior to
             Screening.

          9. Are willing to sign a written informed consent to participate in the study.

             • After initial screening, recruited patients will enter a 2 week placebo
             baseline/eligibility period.

             Patients will be admitted into a sleep lab and will continue to the double blind
             treatment phase if polysomnography (PSG) results meet the following criteria:

         10. Mean LPS ≥30 minutes on both PSG screening nights, with neither night &lt;15 minutes.

         11. Mean total sleep time (TST) ≤390 minutes, or mean WASO ≥30 minutes on both of the 2
             PSG screening nights, with neither night &lt;15 minutes.

        Exclusion Criteria:

          1. According to DSM IV, subjects belonging to the following groups are excluded: 780.59
             (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47
             (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical
             condition)

          2. Subjects suffering from insomnia secondary to other causes according to the sleep
             history questionnaire.

          3. Subjects with sleep disorders detected during PSG inclusion/habituation night, such as
             sleep apnea/hypopnea and periodic leg movement syndrome (with arousal) (PLMAI&gt;10
             and/or AHI &gt; 10 per hour).

          4. Use of psychotropic treatments for the past 3 months and during the study.

          5. Use of strong CYP inhibitors in the preceding 3 months and during the study

          6. Use of benzodiazepines or other hypnotics during preceding two weeks (including all
             benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and
             hydroxyzine).

          7. Alcohol intake - no more than 2 alcoholic drinks per day and any consumption less than
             2 hours before study drug intake.

          8. Immunosuppressive medication in the preceding 3 months and during the study

          9. Severe neurological, psychiatric disorders especially psychosis, anxiety and
             depression

         10. Intercurrent acute or chronic somatic diseases likely to interact with sleep (for
             example: chronic pain from any etiology, benign prostatic hypertrophy likely to
             require surgery in the coming six months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Centers of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research and Sleep Management</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Sleep and Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <results_first_submitted>March 29, 2018</results_first_submitted>
  <results_first_submitted_qc>May 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep latency</keyword>
  <keyword>Sleep maintenance</keyword>
  <keyword>Sleep fragmentation</keyword>
  <keyword>Polysomnography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neu-P11 20mg</title>
          <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="P2">
          <title>Neu-P11 50mg</title>
          <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neu-P11 20mg</title>
          <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="B2">
          <title>Neu-P11 50mg</title>
          <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="16.16"/>
                    <measurement group_id="B2" value="47.4" spread="13.7"/>
                    <measurement group_id="B3" value="51.1" spread="14.52"/>
                    <measurement group_id="B4" value="49.6" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Latency to Persistent Sleep</title>
        <description>The primary efficacy parameter is Latency to persistent sleep (LPS) measured by the PSG at the first two nights (immediate effect) of the double blind treatment period. LPS was summarized at baseline and after two days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the two days was compared, adjusting for the baselinescore. An ANCOVA model was used. Lower score indicates reduction in latency to persistent sleep and thus considered improvement</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neu-P11 20mg</title>
            <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O2">
            <title>Neu-P11 50mg</title>
            <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Latency to Persistent Sleep</title>
          <description>The primary efficacy parameter is Latency to persistent sleep (LPS) measured by the PSG at the first two nights (immediate effect) of the double blind treatment period. LPS was summarized at baseline and after two days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the two days was compared, adjusting for the baselinescore. An ANCOVA model was used. Lower score indicates reduction in latency to persistent sleep and thus considered improvement</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="27.39"/>
                    <measurement group_id="O2" value="-39.1" spread="36.53"/>
                    <measurement group_id="O3" value="-37.5" spread="38.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Awakenings (NOA)</title>
        <description>The secondary efficacy parameter is number of awakenings (NOA) measured by the PSG after 28 nights of the double blind treatment period. NOA was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less awakenings and thus considered improvement.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neu-P11 20mg</title>
            <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O2">
            <title>Neu-P11 50mg</title>
            <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Awakenings (NOA)</title>
          <description>The secondary efficacy parameter is number of awakenings (NOA) measured by the PSG after 28 nights of the double blind treatment period. NOA was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less awakenings and thus considered improvement.</description>
          <units>Awekenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="10.16"/>
                    <measurement group_id="O2" value="-0.1" spread="10.28"/>
                    <measurement group_id="O3" value="0.5" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Wake After Sleep Onset (WASO)</title>
        <description>The secondary efficacy parameter is the duration of wake after sleep onset (WASO) measured by the PSG after 28 nights of the double blind treatment period. WASO was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less waking time and thus considered improvement.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neu-P11 20mg</title>
            <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O2">
            <title>Neu-P11 50mg</title>
            <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Wake After Sleep Onset (WASO)</title>
          <description>The secondary efficacy parameter is the duration of wake after sleep onset (WASO) measured by the PSG after 28 nights of the double blind treatment period. WASO was summarized at baseline and after 28 days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the 28 nights was compared, adjusting for the baseline score. An ANCOVA model was used. Lower score indicates less waking time and thus considered improvement.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="42.04"/>
                    <measurement group_id="O2" value="-36.1" spread="64.12"/>
                    <measurement group_id="O3" value="-13.3" spread="46.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neu-P11 20mg</title>
          <description>Neu-P11 dose of 20 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="E2">
          <title>Neu-P11 50mg</title>
          <description>Neu-P11 dose of 50 mg
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>matching placebo
Neu-P11: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amnon Katz</name_or_title>
      <organization>Neurim Pharmaceuticals (1991) LTD</organization>
      <phone>972-3-768-4906</phone>
      <email>amnonk@neurim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

